Glenmark Pharmaceuticals Limited (GLENMARK) Share Price
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE935A01035
Key metrics
- Market Cap
- ₹70,980 Cr
- P/E Ratio
- 39.53
- EPS
- 63.63
- Book Value
- 372.49
- P/B Ratio
- 6.6
- ROE
- 12.96%
- ROCE
- 36.01%
- Debt / Equity
- 0.06
- Net Margin
- 8.15%
- Revenue Growth
- 27.12%
- Profit Growth
- 30.06%
- Dividend Yield
- 0.3%
- 52W High
- ₹2,537.60
- 52W Low
- ₹1,792.60
- Market Cap Band
- large cap
- Face Value
- 1
Ratios computed from the annual results period ending 2026-03-31.
About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited, together with its subsidiaries, research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides various products in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetes, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 trispecific T cell engager, which is in Phase 1 clinical trial for indication of multiple myeloma; ISB 2301, a Multispecific Immune Cell Activator that is in preclinical trial for solid tumors; ISB 2302, a bispecific immune modulator with an indication for hematologic and solid tumors; and ISB 2501, a trispecific T-cell engager indicated for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 2 clinical trial for the treatment of hidradenitis suppurativa; and telazorlimab and ISB 830-X8, a OX40 antagonist mAb for the treatment of atopic dermatitis. In addition, the company offers Ryaltris, fixed-dose nasal spray for the treatment of allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
- Headquarters
- Mumbai, India
- Employees
- 16,946
- Promoter Holding
- 48.96%
The full Glenmark Pharmaceuticals Limited analysis
Create a free account to open the complete GLENMARK deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.